Despite promising preclinical models for different strategies for BC therapy [2,3,4,5,6], monoclonal antibodies against human epidermal growth receptor 2 (HER2) expression, such as trastuzumab, are currently clinically indicated to ameliorate survival in this group of patients [7,8]. This evidence concerns the gene ERBB2 and breast cancer.